There is a woman in her seventies. Her oncologist has nodded toward cannabis — not a prescription, more of a permissioned shrug. She is exhausted, nauseous, and she does not sleep. Her daughter, also exhausted, drives her forty minutes to a dispensary.
At the counter is a twenty-four-year-old in a hoodie who is genuinely kind and genuinely doing his best. He asks what she is looking for. She does not know. He suggests a tincture, a vape, an edible — three products with three completely different onset times, durations and risk profiles — and she leaves with one of them and a vague instruction to “start low and go slow”.
She gets home. She tries it. It does nothing. Or it does too much. Or it does something strange she cannot describe to anyone, because the doctor does not really want to talk about it, the pharmacist legally cannot, and the budtender is not trained for it.
So she stops.
This is the part of the cannabis industry nobody likes to look at.
When people talk about “the cannabis consumer”, they blur two groups that have almost nothing in common.
The first group is curious. They like learning. They watch videos, they read, they remember strain names, they enjoy the experimentation. For them the market, confusing as it is, works fine. Exploration is part of the value. They have the time, the energy, the openness and frankly the recreational margin to figure it out.
The second group is suffering. They are cancer patients on a third line of treatment. Seventy-year-olds with arthritis who have not slept properly in two years. People with epilepsy, MS, fibromyalgia, late-stage Parkinson's, chronic pain that has taken over the architecture of their day. They did not come to cannabis to explore. They came because they ran out of options.
These patients do not want to become amateur cannabinoid pharmacologists. They want someone — anyone — to say: for your condition, your body, your other medications, your tolerance, here is the protocol. Here is what to take, when, how much, what to expect, and what to do when it does not work the first time.
And nobody is doing that for them.
It is not because people do not care. It is because of how the roles are drawn.
Doctors mostly were not taught cannabis pharmacology. The endocannabinoid system gets, on a generous day, a single lecture. Most physicians are uncomfortable recommending dosages they were never trained on, for products that vary between batches, in a regulatory landscape that punishes specificity. So they say “try it” and stop there.
Pharmacists understand dose-response relationships better than almost anyone — and are walled off from the conversation in most places, because cannabis sits outside the pharmacy supply chain. Where they are in charge, as in Israel, they can help with product selection within the range of the prescription, but they hold no formal role in patient education or titration.
Budtenders are often the kindest people in the chain. But they are retail workers, not clinicians. They rotate quickly. They learn product, not patient. And in most jurisdictions they cannot legally make medical recommendations, so they use deliberately vague language. Asking a budtender to manage a chemotherapy patient's nausea protocol is asking the wrong question of the wrong person.
Researchers know an enormous amount. None of it reaches the seventy-year-old at the counter.
The result is a system where each link has a partial view, and the patient — the person actually swallowing the oil — is expected to integrate it all. That is not a healthcare gap. That is a healthcare hole.
The people most able to advocate for themselves in this market are the people who need the least help. The people who need the most help have the least capacity to advocate.
The curious explorer reads, posts in forums, joins communities, learns the language. Within months they are competent. The cancer patient does not have months. They do not have the energy to read. They do not want to learn the difference between THCV and CBG. They want sleep. They want to eat. They want pain to be a smaller part of their day.
In every other corner of medicine, this is what protocols are for. We do not ask diabetes patients to invent their own insulin regimen. We do not hand chemotherapy patients a menu of cytotoxic agents and say “start low, go slow”. We build protocols, and a trained human walks the patient through them.
Medical cannabis has no equivalent. It badly needs one.
There needs to be a role — a real one, with a name, a training pathway and a seat at the table — whose job is the patient's protocol. Not the product. Not the strain. Not the SKU.
I work with patients in this gap, and I see the same pattern repeatedly: the people who would benefit most from medical cannabis are the ones least served by how the market is shaped. Not because anyone is malicious. Because responsibility for their care is diffused across roles that were never designed to hold it.
I do not think this is unsolvable. I think it is unattended.
A version of this piece first appeared on LinkedIn. This version has been rewritten and expanded.
The free WIZDOM Self-Check is nine questions, takes about ninety seconds, and sends you a personalised four-document toolkit.
Take the free Self-Check